How Supplier Evaluations And Component Neutrality Can Enhance Supply Chain Assurance

By Derek Pendlebury, Ph.D., Global Sales Director, BioPharma, CPC

The process of developing a new biologic is complex, expensive, and time-consuming. Biopharmaceutical companies routinely gather product information, review specifications, and negotiate prices during the development and design phase of the biological manufacturing process. Where products, technologies, and suppliers that have been previously used are selected for use in a new process, the manufacturer’s already established database can be accessed to ensure product suitability and performance, and to confirm the supplier’s ability to support production over the long term.

However, when a new product, technology, or supplier is selected, it is essential for a manufacturer to take a detailed assessment not only of their proposed supplier, but also the supplier’s own supply chain and even beyond. This is especially important when selecting suppliers of single-use assemblies